For the quarter ended December 2025, Bausch Health (BHC) reported revenue of $2.8 billion, up 9.3% over the same period last year. EPS came in at $1.08, compared to $1.15 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $2.7 billion, representing a surprise of +3.38%. The company delivered an EPS surprise of -10.5%, with the consensus EPS estimate being $1.21.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Total Bausch + Lomb revenues: $1.41 billion compared to the $1.37 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
- Revenues- Diversified Products: $255 million versus $233.84 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11.8% change.
- Revenues- Bausch + Lomb- Vision Care: $778 million versus the two-analyst average estimate of $778.13 million. The reported number represents a year-over-year change of +7.6%.
- Revenues- Bausch + Lomb- Surgical: $249 million compared to the $239.46 million average estimate based on two analysts. The reported number represents a change of +7.8% year over year.
- Revenues- Total Bausch Health (excl. B+L): $1.39 billion compared to the $1.33 billion average estimate based on two analysts. The reported number represents a change of +8.8% year over year.
- Revenues- International: $306 million compared to the $280.41 million average estimate based on two analysts. The reported number represents a change of +9.7% year over year.
- Revenues- Solta Medical: $137 million compared to the $143.46 million average estimate based on two analysts. The reported number represents a change of -0.7% year over year.
- Revenues- Salix: $693 million compared to the $669.92 million average estimate based on two analysts. The reported number represents a change of +9.3% year over year.
- Revenues- Bausch + Lomb- Pharmaceuticals: $378 million versus the two-analyst average estimate of $353.78 million. The reported number represents a year-over-year change of +16%.
View all Key Company Metrics for Bausch here>>>
Shares of Bausch have returned -11.8% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch Health Cos Inc. (BHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
